Loading…
Loading…
BCTXZ is a hybrid capital security, not common stock.
This listing is a capital note, preference share, or similar instrument associated with BriaCell Therapeutics Corp. Warrant. Data providers report company-level figures against it, so fundamentals, valuation multiples, and dividend history on this page describe the issuing company — not this instrument — and its market capitalization cannot be computed reliably, so it is not shown. The quoted price is the instrument's own.
BCTXZ does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for BCTXZ and 80,000+ other tickers.
See exactly how BCTXZ's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for BCTXZ and 80,000+ other tickers.
BriaCell Therapeutics Corp., a biotechnology company based in West Vancouver, Canada, is intensely focused on immuno-oncology, dedicated to engineering novel immunotherapies for cancer treatment. Its flagship compound, Bria-IMT, is a whole-cell cancer vaccine presently in Phase I/IIa clinical development, where it's being evaluated in conjunction with the investigational immunotherapy retifanlimab. The company's pipeline also includes Bria-OTS, a personalized, ready-to-use immunotherapy intended for advanced breast cancer, and BriaDx, a diagnostic tool for determining patient HLA types…
No recent news available.